Inclusion Criteria:

- History of breast cancer or endometrial cancer confirmed at MSKCC

- Have completed primary treatment (surgery, radiation therapy, or chemotherapy), with
the exception of endocrine therapy and Trastuzumab

- Breast cancer patients must be currently on adjuvant aromatase inhibitors

- Endometrial cancer patients must have underwent surgical treatment (total abdominal
hysterectomy ([TAH]/BSO)) and radiation therapy (external beam radiation therapy
[EBRT] or IVRT)

- At least 3 months post-treatment but not greater than 5 years post-treatment
(exception: AIs are allowed)

- Currently have no clinical evidence of disease

- Menopausal at study entry as described by:

- Surgical menopause (TAH/BSO), or

- Age ≥ 50 years and cessation of menstruation for at least 1 year, or

- Age <50 years and cessation of menstruation for at least 1 year with estradiol level
in post-menopausal range, or

- Rendered post-menopausal with the use of LHRH agonist Reporting being bothered by
vaginal symptoms of estrogen deprivation (i.e., vaginal dryness or discomfort [pain
with intercourse or examination])

- Without history of other cancers (excluding non-melanoma skin cancer)

- Women at least 18 years of age

- Able to read and speak English

- Able to participate in the informed consent process

Exclusion Criteria:

- Inability to provide informed consent

- Vaginal bleeding of unknown etiology within 12 months of study entry

- Currently taking hormone replacement therapy [local or systemic] (Patients must
discontinue for 4 weeks in order to be eligible prior to study enrollment)